Photocure and Artera collaborate to advance bladder cancer diagnosis
This collaboration utilizes Photocure's BLC registry and ArteraAI's bladder test to validate biomarkers, enhancing clinicians' ability to predict disease progression and tailor therapies for bladder cancer patients.
Photocure ASA, the Bladder Cancer Company, and Artera have entered into a joint research initiative aimed at enhancing AI-powered digital pathology for bladder cancer. The partnership utilizes Photocure's blue light cystoscopy (BLC) registry in bladder cancer and the ArteraAI Bladder Test.
The research collaboration will provide Artera with access to high-quality data from the Photocure U.S. BLC registry to further validate the ArteraAI Bladder Test. Together, the companies will utilize real world evidence to help urologists more effectively identify bladder cancer and manage its treatment. Unlike many other cancers, there are fewer well-established biomarkers in bladder cancer, which currently limits clinicians from personalizing treatment options. The partnership between Photocure and Artera is dedicated to advancing research that guides smarter treatment decisions and helps patients receive therapies best suited to their disease.
The objectives of using the BLC registry's long-term clinical practice data are to develop, evaluate, and optimize the performance of Artera's multimodal AI (MMAI) histopathology biomarkers in patients with non-muscle invasive bladder cancer (NMIBC). The joint research aims to validate the prognostic and predictive capabilities of the ArteraAI Bladder by addressing critical clinical questions.
